RedChip Global Online Growth Conference Nasdaq...

January 25, 2017

THE ONCOLOGY DIAGNOSTICS PARTNER FROM BENCH TO BEDSIDE

RedChip Global Online Growth ConferenceNasdaq

(CGIX)

2017 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics 2

Forward-Looking Statement

These slides may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act

of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology,

clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other

statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute

forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will,"

"believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements.

Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the

development and/or commercialization of potential products, risks of cancellation of customer contracts or

discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of

clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights

and other risks discussed in the Cancer Genetics, Inc. Forms 10-K for the year ended December 31, 2015 and 10-Q for

the quarter ended September 30, 2016 along with other filings with the Securities and Exchange Commission. These

forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update

these forward-looking statements.


EVERYTHING WE DO AT CGI IS

FOCUSED ON ONE KEY IDEA…

…DELIVER INNOVATION & PATIENT

VALUE BY PROVIDING THE MOST

COMPREHENSIVE CAPABILITIES IN

ONCOLOGY DIAGNOSTICS &

PRECISION MEDICINE


Large, Global Market Opportunities $458B GLOBAL ONCOLOGY SPEND BY 2030

Global Footprint Created by Highly

Strategic M&A3 TRANSFORMATIVE ACQUISITIONS IN 2014 & 2015

Strong & Growing Partnerships with Leading

BioPharma

CONTRACTS WITH 8 of 10 TOP BIOPHARMA+650% INCREASE WITH BIOPHARMA(1) CUSTOMERS

FROM 2012 TO 2015

Innovation Engine & Expertise Driven By

Key Collaborations18 RESEARCH COLLABORATIONS WITH

LEADING INSTITUTIONS

Unique, Proprietary Portfolio of Genomic

Tests & Panels

20 COMMERCIALLY LAUNCHED TESTS

49 US PATENTS AND 100+ FOREIGN PATENTS

Diversified & High Growth Revenue Streams 77% Revenue Growth 2014-15 / 43% 4-YEAR CAGR

World-Class Management Team 100+ CUMULATIVE YEARS OF EXPERIENCE

Investor Highlights: Cancer Genetics Addresses

the Trends in Oncology from Bench to Bedside

(1) In signed contracts & potential revenue


Our Mission is to be the Oncology Diagnostics Partner

of Choice from Bench to Bedside

DELIVERING CRITICAL GENOMIC

INSIGHTS TO PHYSICIANS

TO PERSONALIZE TREATMENT

& IMPROVE OUTCOMES

CLINICAL

TRIALSRESEARCH

PATIENT

CARE

PARTNERING WITH LEADING

RESEARCH INSTITUTIONS TO

DRIVE INNOVATION AND

DEVELOP NEW INSIGHTS

PROVIDING UNPARALLELED

EXPERTISE TO BIOPHARMA

COMPANIES FOR IMPROVED

THERAPEUTIC DEVELOPMENT

INNOVATION & EXECUTION


KEY M&A

CRITERIA

TARGETED

ACQUISITIONS

90,000 SQ. FT.

GLOBAL FOOTPRINT

Response Genetics, Inc. (October 2015)

Leading solid tumor testing franchise with content in lung, colorectal, skin

and brain cancers as well as FDA-cleared Tissue of Origin Test®

Strong commercial presence in the Western & Southeastern US with 3,000+

customers

Established community oncologists & pathologists sales channel

CALIFORNIA

BioServe Biotechnologies, India (August 2014)

First company to provide DNA synthesis, DNA sequencing & related

services in India

Customers include leading cancer research institutes (ICMR, CSIR) as well

as major pharmaceutical and biotechnology companies

Gentris, Corp. (July 2014)

Leading global provider of biopharma, discovery, pharmacogenomics, next-

generation sequencing, genotyping, and biorepository services

US FDA-compliant lab in Zhanjiang Hi-Tech Park, Shanghai, China

RESPONSE GENETICS

LOS ANGELES, CA

Active and Successful M&A Strategy Focused on Growth,

Capabilities, and Global Footprint

1. Access to Differentiated

Oncology Testing

Capabilities & Content

2. Ability to Expand

Geographic Footprint Into

Key, High Growth Markets

3. Opportunity to Strengthen

& Diversify Customer Base

Across Research,

BioPharma & Clinical End

Markets

4. Ability to Realize

Commercial & Operational

Synergies

5. Shared Cultural Values

Based on Innovation & Teamwork

BIOSERVE

HYDERABAD

INDIA

GENTRIS

SHANGHAI

CHINANORTH CAROLINA

RTP


The Oncology Marketplace & Opportunity

SPENDING ON ONCOLOGY TESTING

Source: IMS Health MIDAS, Dec. 2014; IMS Health Market Prognosis, March 2015. ISR Reports October 2015 & CGI Analysis

POTENTIAL BUYING CENTERS

Community

Hospitals Regional

Cancer Centers4,000+ U.S.

HOSPITALS

3,000+U.S. CLINICAL

TRIALS FOR ALL

CANCER TYPES

Pharmaceutical &

Biotechnology

Companies

200+RESEARCH

CENTERS

IN THE U.S.

Universities &

Research Centers

85% ONCOLOGY

PATIENTS

Treated in

Community Setting

$42B ~$57B

3.984.68

3.72

5.410.84

1.02

2015 2020

Clinical

Biopharma

Discovery

$8.5 Bn

$11.2 Bn


Primary Growth Drivers During 2016-17

• Key immuno-markers are

already FDA cleared and

in market: PD-1 & PDL-1

• CGI offers ALL the PD-L1

companion diagnostic

tests available on the

market for immuno-

oncology therapies

• Multiple partnerships in

development

Immuno-Oncology Healthcare Systems

• Need for a partner that

can provide unique tests

along with day-to-day

collaboration for patient

needs

• Increasing clinical and

economic acceptance of

CGI’s focused NGS

Panels (Lymphoma,

Myeloid, Lung, etc.)

Testing Innovation

• Launch of Multiple Myeloma

panel with Mayo Clinic

• More marketing focus and

data on FDA-cleared Tissue

of Origin® and CE-cleared

FHACT® for Cervical Cancer

• Launch of focused, multi-

gene liquid biopsy tests for

lung and renal cancer in

upcoming quarters

Biopharma Partners

• Pharmas need companies

that can provide testing,

innovation and patient

insights

• CGI has both content and

capabilities that are unique

or in high market demand

• In discussions with several

pharma companies for

large scale partnerships


TOTAL REVENUE AND FUTURE GROWTH(1)

(1) Approximate expected future revenues under signed contracts with biotechnology & pharma customers for testing & services to support currently planned clinical trials

Strong and Growing Relationships with Leading

Biopharma Companies

$0.6M$2.7M

$5.6M

$11.6M

$9.3M

2012 2013 2014 2015 9 months

$4.3M

$6.6M

$10.2M

$18.0M

$19.8MCGI HAS CONTRACTS

WITH TOP BIOPHARMA

COMPANIES

8 of 10

NUMBER OF CLINICAL

TRIALS CGI IS ACTIVELY

SUPPORTING WITH ITS

TESTING, GENOMIC

SERVICES, & BIOMARKER

CAPABILITIES

120+

+$40MANTICIPATED

FUTURE

REVENUES

FROM

BIOPHARMA

CUSTOMERS

($ in millions)

2016


CGI COLLABORATIONS DRIVE

INNOVATION AND IMPROVED

PATIENT FOCUS IN

DEVELOPING OUR UNIQUE

PORTFOLIO


Collaborations with World-Renowned Cancer Research

Institutions

Disease Target Collaboration Highlights

Beth Israel Deaconess Medical Ctr DLBCL (Diffuse Large B-Cell Lymphoma) Biomarker-based outcome prediction using Focus::Lymphoma™ and MatBA®-DLBCL

Cleveland Clinic Kidney Cancer Genomic marker validation

Columbia University AML, MDS, and Myeloid Cancers (Acute Myeloid Leukemia, Myelodysplastic Syndromes)

NGS panel development

Groupe Hospitalier Pitié Salpétriêre, Paris Kidney Cancer Analysis of biomarker variability by array-CGH & NGS

Huntsman Cancer Institute, Univ of Utah Kidney Cancer Evaluation of biomarkers of response using Focus::Renal™ & array-CGH

Kamineni Hospital, India Cervical Cancer FHACT® evaluation

Keck Medicine of USC DLBCL and FL (Follicular Lymphoma) Biomarker investigation

Memorial Sloan-Kettering Cancer Ctr Kidney Cancer Array-CGH & NGS core needle biopsy analyses & biomarkers assoc. w/metastasis

Moffitt Cancer Center CINV and PGx Prediction of side effects associated with chemotherapy (CINV)

National Cancer Institute Cervical Cancer FHACT® development & cervical cancer screening trials

North Shore LIJ Health System CLL/SLL CLL/SLL validation & BTK inhibitor resistance

University of Alabama Central Nervous System Lymphoma Biomarker investigation

University of Iowa Cancer Center DLBCL, Lymphoma MatBA®-DLBCL and Focus::Lymphoma™ validation

Westchester Medical Center Central Nervous System Lymphoma Genomic biomarker identification using UroGenRA®


2016 Collaboration Highlights

H3 Biomedicine Inc. (H3) selected CGI to provide clinical biomarker

services for H3’s lead oncology drug candidate H3B-8800: the first

ever gene splicing anticancer therapeutic agent being developed for

the potential treatment of select blood-based cancers

Announced results at ASCO with HTG, Keck School of Medicine at

USC, and Japan Clinical Cancer Research Organization of using

immune-related genes to identify subtypes of patients associated

with clinical outcome in metastatic colon cancer

Huntsman Cancer Institute at University of Utah, Pfizer, and CGI

entered a collaboration for the validation of CGI’s NGS-based kidney

cancer panel, which includes a signature for the prediction of response

to Sunitinib®, and the development of cell-free DNA assay for disease

monitoring.


Unique, Proprietary Portfolio of Genomic Tests & Panels

RESEARCH &

DISCOVERY

CLINICAL

DEVELOPMENT

COMMERCIAL

DEVELOPMENT

Provide comprehensive

and technology

agnostic methodologies

Drive novel discovery

and development

through partnerships

with key thought

leaders

Target unmet and

critical disease states

Meaningfully impact

and improve clinical

trials and patient care

MARKET

ENTRY

(1) Pipeline of projects may change based on business or scientific rationale

(2) Joint Venture with the Mayo Clinic

Guiding Principals for

Portfolio Development(1)

MULTIPLE MYELOMA

FOLLICULAR LYMPHOMA

LUNG CANCER

ONCOSPIRE

GENOMICS(2)

BLOOD

CANCERS

MYELOID NGS PANELS [AML; MDS; MPN; OTHER MYELOID MALIGNANCIES] 4 TESTS IN MARKET

MATBA® FOR B-CELL CANCERS [CLL&SLL; DLBCL; FL; MCL] 4 TESTS IN MARKET

LYMPHOMA NGS PANELS [CLL; DLBCL&FL; MCL; OTHER LYMPHOMAS] 5 TESTS IN MARKET

SOLID

TUMORS

TISSUE OF ORIGIN® [FDA-CLEARED] TEST IN MARKET

UROGENRA®-KIDNEY TEST IN MARKET

FHACT® CERVICAL TEST IN MARKET

FOCUS::CANCER HOTSPOT™ [SOLID TUMORS] TEST IN MARKET

FOCUS::ONCOMINE™ [SOLID TUMORS] TEST IN MARKET

FOCUS::RENAL™ TEST IN MARKET

COMPREHENSIVE PHARMACOGENOMICS (PGX) PANEL

HEREDITARY BREAST & OVARIAN CANCER (HBOC) PANELHEREDITARY TEST IN MARKET


OncoSpire Genomics

Joint Venture Between Cancer Genetics & Mayo Clinic

• Joint venture based in Rochester, MN

• Goal: to develop tests that will become the gold standard in

diagnosing and managing patients with selected disease targets

• Diseases with known clinical dilemmas were selected and informed by

clinicians in the Mayo Clinic network

• OncoSpire has the rights to druggable targets that are discovered

PROJECT PIPELINE(1):

~115,000NEW CASES

PER YEAR

GLOBAL

MULTIPLE MYELOMA

LUNG CANCER

FOLLICULAR LYMPHOMA

~1.8MNEW CASES

PER YEAR

GLOBAL

RESEARCH & DISCOVERY CLINICAL DEVELOPMENT COMMERCIAL DEVELOPMENT LAUNCH & MARKET ENTRY

Commercially Launching

~130,000NEW CASES

PER YEAR

GLOBAL

(1) Pipeline of projects may change based on business or scientific rationale


Design & Architecture

220 genes & coding regions [~1MB comprising 4,048 tiled regions]

CLIA-approved (April 2016)

Risk / Outcome &

Cell of Origin

Clinical Targets

Associated with

Drug Pathways

BCR/PI3K/WNT

Located within

Aberration

(DLBCL Only)

ABCA13 BIRC3 CDKN2B EPHA7 HIST1H1C JAK2 NFKBIB PIK3CG RAF1 SYK

ABCA3 BLK CIITA ERBB3 HIST1H1E KDM6B NLGN2 PIK3R1 RAPGEF1 SYNJ2

ABCC4 BLNK CNOT6L ETS1 HIST1H2BC KDR NLK PIK3R2 RB1 TBL1XR1

ABCC9 BRAF COL16A1 EZH2 HIST1H3B KIT NOTCH1 PIKFYVE RGS4 TCF4

ABL1 BRD4 CREBBP FAS HIST1H4I KLHL6 NOTCH2 PIM1 RHOA TEC

ACTB BTG1 CSMD3 FAT2 HIST2H2BE KRAS NOX4 PLCB1 ROBO2 TET2

ACTN1 BTG2 CSNK1D FAT4 HRAS LRP1 NR3C1 PLCB4 ROCK2 TLR2

ADAM10 BTK CTBP2 FBXO11 ID3 LRP6 NRAS PLCD1 ROS1 TMEM30A

AHR CARD10 CTNNA2 FGFR1 IGSF1 LRRC7 NTRK1 PLCD3 RRAGC TNF

AKT CARD11 DCC FLT1 IKBKB LYST TENM4 PLCE1 S1PR2 TNFAIP3

APC CARM1 DCP1B FOXO1 IKZF1 MALT1 OGDHL PLCG2 SALL3 TNFRSF11A

APC2 CCND1 DDX21 FOXP1 IKZF3 MAP2K1 P2RX5 PLCZ1 SEMA6C TNFRSF14

AQR CCND3 DGKZ FYN INPP5B MED12 P2RY8 POT1 SF3B1 TNIK

ARID1A CD22 DHDH GCC2 IRF4 MEF2B PARP1 POU2AF1 SGK1 TNRC6B

ATM CD36 DLC1 GNA13 IRF8 MLL2 PDCD1 POU2F2 SI TP53

ATP11C CD58 DSEL GNAI2 ITGB3 MLL3 PDGFRA PRDM1 SLC17A6 TRAF2

ATP6AP1 CD70 DTX1 GPR112 ITPK1 MLLT6 PDK1 PRKCA SLC30A4 TRIM8

B2M CD79A DUSP2 GRB2 ITPKB MRGPRF PIK3AP1 PRKCB SMARCA4 UBR5

BAP1 CD79B DUSP27 GRIN2A ITPR1 MTOR PIK3C2A PRKDC SOCS1 VAV1

BCL10 CDIPT EBF1 GSK3B ITPR1 MYC PIK3C2G PTEN SP140 WHSC1

BCL2 CDK4 EIF2AK4 HCK ITPR2 MYD88 PIK3C3 PTPN13 STAT3 XPO1

BCL6 CDKN2A EP300 HIST1H1B JAK1 NFKBIA PIK3CD PYHIN1 STAT6 ZMYM3


Design & Architecture

ABL1 CARD11 ERBB2 JAK2 PCNA RBAK STAG2

AFF1 CCDC120 FGFR1 KDM5C PDGFRB-- RHEB TET2

AKT1 CCND2 FLT3 KIT PGLYRP3 ROS1 TNC

AKT2 CDH4 FYN MAGEC1 PIK3CA SCARB2 TP53

ALK CUL1 GLI3 MAPK14 PIK3CG SETD2 TSC1

ARID1A-- DAXX GOLGA5 MET PTCH1 SFXN4 TSC2

AXL DFNA5 GUSB MTOR PTEN SMO UBE2D1

BAP1 DIO2 HIF1A NDRG1 RAF1 SMOX VHL

BMPR1B DST HSP90AA1 NPNT RALGAPA1 SOX4 ZFPM2

BRAF EGFR IFNB1 PBRM1 RAPGEF1 SPRED1 ZNF800

BRINP2 EPHB4 ING4 PCK1 RASSF2 SRC

Renal Extended™ [76 genes] and Focus::Renal™ [32 genes]

rs7121 (GNAS1) rs11549465 (HIF1A) rs1126647 (IL8) rs4073 (IL8)

rs11762213 (MET) rs699947 (VEGFA) rs9582036 (VEGFR1)

Focus::Renal™

NGS Panel [32 genes]

Frequently

Mutated Genes

=

FDA-Approved

Drug Targets

=

Key:

3. GENOME-WIDE GAIN/LOSS ASSESSMENT

1. GENE MUTATION ASSESSMENT

2. PROGNOSTIC SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS)

Diagnosis,

Prognosis,

& Therapy

Response

Renal Cell

Carcinoma

(RCC)


CGI OPERATES AT THE

FOREFRONT OF THE ERA

WHERE GENOMIC AND

IMMUNE MARKERS WILL

ENABLE PRECISION MEDICINE


Our Three Pillars of Innovation

HIGH SENSITIVITY

LIQUID BIOPSY AND

CELL-FREE ANALYSIS

• Portfolio Updates

Anticipated launch of focused, multi-gene liquid biopsy tests for lung

and renal cancer in upcoming quarters

• Oncomine™ Lung cfDNA Assay

Detection levels down to 0.1% with 90% sensitivity & >98% specificity

for point mutations and indels using only a single blood sample

UNIQUE CONTENT

VIA PARTNERSHIPS

& COLLABORATIONS

• Mayo Clinic

Oncospire Genomics joint venture targeting hematological cancers

• Columbia University

Genomic signatures for myelodysplastic syndromes and AML

• Huntsman Cancer Center

Patient response to kidney cancer frontline therapies

IMMUNO-ONCOLOGY

CAPABILITIES THAT ARE

INDUSTRY LEADING

• HTG Collaboration

Expression of genes implicated in patient immune responses to tumors

• Dako / Ventana CDx

Dako 22C3 and Ventana SP263 CDx test for KEYTRUDA®

• Unique Immuno-Oncology Panel via Flow Cytometry

Commercialization of Comprehensive IO Panel via Flow Cytometry

3

2

1


Immuno-Oncology: Greater Insights Require Integrated

Information From Multiple Technologies

AND HAS THE

POTENTIAL TO

IMPACT UP TO 60%BY 2024,

IMMUNO-ONCOLOGY

DRUG SALES ARE

EXPECTED TO REACH$35B

OF ALL

CANCER

PATIENTS

Source: IMS Health

IMMUNOPHENOTYPING

& FLOW CYTOMETRY

TRANSCRIPTOME PROFILING

& SEQUENCING VIA NGS

IMMUNOHISTOCHEMISTRY

(IHC)

to assess immune response

against cancers

to measure expression

levels of drug targets

to detect critical biomarkers

such as PD-L1 [FDA-APPROVED]

CANCER

GENETICS’

EXTENSIVE

APPROACH

IN IMMUNO-

ONCOLOGY:

CANCER GENETICS is

listed by MERCK as a

National Reference

Lab for KEYTRUDA® -

a drug that will be

impacting $7.8 BN IN

SALES BY 2025


Combinations of Targeted & Immuno-Oncology Drugs Will

Improve Outcomes and Drive Biomarker Testing

Expected Combination Regimen

Launches in Oncology

48 7 7

1319

15

34

0

10

20

30

40

2014 2015 2016 2017 2018 2019 2020 2021+

Many combinations will launch over the

next five years with an inflection point

near 2020-2021

Hematology and breast combos will

continue to dominate through 2018

After 2018, solid tumor combos will

increase dramatically – especially for

lung cancer and melanoma

Combinations will incorporate targeted

and immuno-oncology agents and are

likely to have an additive or synergistic

therapeutic effect

Sources: CenterWatch, FDA, clinicaltrials.gov, IMS R&D LifeCycle, IMSCG Analysis,

Cell 161 April 9, 2015 Elsevier Inc.

Time

Perc

ent S

urv

ival

Possibility for Improved Overall Survival

as a Result of Combination Therapy

Chemotherapy Immune Checkpoint Therapy

Genomically

Targeted Therapy

Combination with Genomically Targeted

Agent and Immune Checkpoint Therapy


Targeted Clinical Trials Drive Revenue Today and

Market Share in the Future

REVENUE TODAY FOR BIOPHARMA SERVICES FUTURE REVENUE IN CLINICAL CARE

TODAY FUTURE

>15MIGHT TRANSFORM CANCER CARE

BASED ON CGI’S ESTIMATE OF A

15% APPROVAL RATE 3-5POTENTIAL COMPANION DX

TO ACCELERATE CLINICAL

GROWTH & PROFITABILITYCLINICAL TRIALS WITH CGI120+


Application Submitted

Term Through 2022

Term Through 2023

Term Through 2027

Term Through 2030

Term Through 2030

Term Through 2031

2 US Patents | EU | India | Canada

Mature B-Cell Neoplasms

4 US Patents

Tissue of Origin

2 US Patents | EU

Renal Cortical Neoplasms

13 US Patents | PCT | AU | CA | China | Japan

Gene Expression

2 US Patents | Canada

Chromosomal Analysis Using FISH

2 US Applications Filed | PCT

Gynecological Cancers & Precancers

3 US Patents | PCT

HPV-Associated Cancers

Disease-Focused Patent Portfolio: 100+ Global Patents

SELECT SIGNIFICANT PATENTS INCLUDE:


Strong Record of Continuous Growth

FULL YEAR TOTAL REVENUE BY YEAR / CATEGORY

($ IN MILLIONS)

BIOPHARMA

CLINICAL

DISCOVERY

OTHER

2012 2013 2014 2015 9 mos2016

$4.3M

$6.6M

$10.2M

$18.0M

Q3 TOTAL REVENUE BY YEAR / CATEGORY

($ IN MILLIONS)

Q3 2013 Q3 2014 Q3 2015 Q3 2016

$1.7M

$3.2M

$4.0M

$6.8M$19.8M

BIOPHARMA

CLINICAL

DISCOVERY

OTHER


Cancer Genetics Summary Statement of Operations

SUMMARIZED INCOME STATEMENTS (dollars in thousands)

SUMMARIZED BALANCE SHEET (dollars in thousands)

Q3 2015 Q2 2016 Q3 2016

REVENUE $4,001 $7,000 $6,750

Gross Profit 898 2,716 2,306

Gross Margin (%) 22% 39% 34%

Research & Development 1,802 1,680 1,594

Sales & Marketing 1,243 1,379 1,054

General & Administrative 3,487 3,658 3,701

OPERATING PROFIT (Loss) ($5,634) ($4,001) ($4,043)

NET INCOME (Loss) ($5,212) ($4,028) ($3,745)

Actual 09/30/16

CASH & CASH EQUIVALENTS $10,716

STOCKHOLDERS’ EQUITY $27,847


FULL YEAR 2015 - $5.7MCGI PAYMENT HISTORY(CLINICAL REVENUES ONLY)

COVERED LIVES REPRESENTED BY AGREEMENTS

WITH NATIONAL INTEGRATED NETWORKS

MORE THAN

180M

Clinical Reimbursement Mix & Payer Coverage

Q3 2016 - $2.7MCGI PAYMENT HISTORY(CLINICAL REVENUES ONLY)

29%

39%FY 2015

REGIONAL

AND NATIONAL

PAYERS

MEDICARE

COMMERCIAL

PAYERS

32%

DIRECT BILL 14%

52%Q2 2016

REGIONAL

AND NATIONAL

PAYERS

MEDICARE

COMMERCIAL

PAYERS

34%

DIRECT BILL


Growth & Revenue Drivers - Portfolio

CGI is working on a number of initiatives that will add accelerated growth to our core

business that include additions to the portfolio, new partnerships and additional

service offerings

1. Launch of Hereditary Cancer Testing Panel, initially HBOC Q1

• Expect reimbursement in the range of $700 to $2,000 per test

• Major pharma has already ordered 200+ tests

2. Launch of Multiple Myeloma NGS Panel with Mayo Clinic Q2

• Expect reimbursement in the range of $700 to $2,000 per test

• Already in usage by 2 major pharma companies

• In discussions to develop into a focused complementary Dx for monitoring

3. Launch of IO focused NGS Panel for Biopharma Studies Q1

• Awarded one deal that will take place in India and US with IVD company

• Discussions for another deal for an IO panel on NGS with major pharma

4. Launch of Liquid Biopsy for Lung Cancer Profiling Q2 & Q3

5. Launch of Liquid Biopsy for Kidney Cancer Q2 & Q3

ITEM TIMEFRAME


CGIX Has Multiple Points of Strategic Advantage & Are

Leading to Long-Term, Differentiated & Durable Value M

oats

of D

iffe

ren

tiatio

n -

Separa

ting fro

m the P

ack

Comprehensive

Cancer Testing

Portfolio

Blood Cancers

Solid Tumors

Hereditary

Multiple

Technologies

Oncology

Partner

of Choice

Provide both

testing and

disease

management

programs based

on informatics

Become a

collaborative,

trusted partner

of pharma with

upside

Global

Infrastructure

Secure broader

reach through

partnerships and

select acquisitions

Invest in

operational

improvements

and IT to achieve

seamless global

operations

Collaborative

Innovation

Engine

Access to 20+

leading oncology

focused

institutions and

research groups

to lower cost of

development and

create new IP

and tests

Disease

Focused

Knowledge

Targeting

specific

cancers

provides both

depth and

efficiency of

coverage

Our strategy is to further accelerate our significant competitive

differentiators through operations and also marketing and

collaborative awareness with customers

WORKING TOGETHER

TOWARDS BUILDING A HIGHLY

DURABLE LEADER IN

ONCOLOGY AND PRECISION

MEDICINE


Board of Directors

Panna Sharma

CEO & president of Cancer Genetics

General Manager of OncoSpire Genomics

Previously managing partner/founder of TSG Partners

70+ buy & sell-side transactions (healthcare companies)

Raju S.K. Chaganti, PhD

Founded CGI & served as Chairman until 2014

Internat’ly recognized leader in molecular genetics

Co-discovered lymphoma & kidney cancer patents

Incumbent of the William Snee E. Chair at MSKCC

John Pappajohn Non-Executive Chairman

Involved in 100+ start-up companies

Served as director of 40+ public companies

Currently on boards of: American CareSource

Holdings; ConMed Healthcare Mgmt; CNS Response

Howard McLeod, PharmD g

Personalized Medicine Medical Director at Moffitt

Founding Director of the Univ. of NC Institute for

Pharmacogenomics (PGx) & Individualized Therapy

475+ peer-reviewed papers (PGx, applied therapeutics)

Michael J. Welsh, MD c, g

Investigator at the Howard Hughes Medical Inst.

Roy J. Carver Biomed Research Chair in Internal

Medicine & Molecular Physiology & Biophysics

Director of Univ. of Iowa Inst. for Biomed Discovery

Geoffrey Harris, CFA a

30+ years experience as healthcare analyst & portfolio

manager for biotech/life sci companies

Portfolio manager/managing partner at c7 Advisors

Previously: Cantor Fitzgerald; Gleacher & Company

Ted Cannon a,c

Founder & President of the Clinical Research Center of

Cape Cod

Previously at Franey Medical Labs; Pharmacia

Diagnostics; Alletess

Franklyn Prendergast, MD, PhD a, c, g

Director of Mayo Clinic for Individualized Medicine (Retired)

Currently on boards of: Translational Genomics

Research Inst.; Infectious Disease Research Inst.;

DemeRx, Inc.; Ativa; Eli Lilly & Co.

a: Audit Committee c: Compensation Committee g: Governance and Nominating Committee


Large, Global Market Opportunities $458B GLOBAL ONCOLOGY SPEND BY 2030

Global Footprint Created by Highly

Strategic M&A3 TRANSFORMATIVE ACQUISITIONS IN 2014 & 2015

Strong & Growing Partnerships with Leading

BioPharma

CONTRACTS WITH 8 of 10 TOP BIOPHARMA+650% INCREASE WITH BIOPHARMA(1) CUSTOMERS

FROM 2012 TO 2015

Innovation Engine & Expertise Driven By

Key Collaborations18 RESEARCH COLLABORATIONS WITH

LEADING INSTITUTIONS

Unique, Proprietary Portfolio of Genomic

Tests & Panels

20 COMMERCIALLY LAUNCHED TESTS

49 US PATENTS AND 100+ FOREIGN PATENTS

Diversified & High Growth Revenue Streams 77% Revenue Growth 2014-15 / 43% 4-YEAR CAGR

World-Class Management Team 100+ CUMULATIVE YEARS OF EXPERIENCE

Investor Highlights: Cancer Genetics Addresses

the Trends in Oncology from Bench to Bedside

(1) In signed contracts & potential revenue

Thank youNasdaq

(CGIX)

For further information, please contact us at [email protected]

CGI Headquarters

201 Route 17 North

Rutherford, NJ 07070

Phone: +1 201-528-9200

RUTHERFORD, NJ

Research Triangle Park

133 Southcenter Court

Morrisville, NC 27569

Phone: +1 919-465-0100

RALEIGH, NC LOS ANGELES, CA

1640 Marengo Street

Fourth Floor

Los Angeles, CA 90033

Phone: +1 323-224-3900

#3-1-135/1A CNR Complex

Mallapur Main Road, R.R. Dst.

Hyderabad – 500 076, Telangana

Toll-free: +91 040-2717-8178

HYDERABAD, INDIA

781 Cai Lun Road, Room 803

Shanghai 201203

P.R. China

Toll-free: +86 21-5049-5700

SHANGHAI, CHINA

mailto:[email protected]

RedChip Global Online Growth Conference Nasdaq...

Documents

Transcript of RedChip Global Online Growth Conference Nasdaq...